RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma

Marina N. Nikiforova, Roy A. Lynch, Paul W. Biddinger, Erik K. Alexander, Gerald W. Dorn, Giovanni Tallini, Todd G. Kroll, Yuri E. Nikiforov

Research output: Contribution to journalArticle

505 Citations (Scopus)

Abstract

A series of 88 conventional follicular and Hürthle cell thyroid tumors were analyzed for RAS mutations and PAX8-PPARγ rearrangements using molecular methods and for galectin-3 and HBME-1 expression by immunohistochemistry. A novel LightCycler technology-based method was developed to detect point mutations in codons 12/13 and 61 of the H-RAS, K-RAS, and N-RAS genes. Forty-nine percent of conventional follicular carcinomas had RAS mutations, 36% had PAX8-PPARγ rearrangement, and only one (3%) had both. In follicular adenomas, 48% had RAS mutations, 4% had PAX8-PPARγ rearrangement, and 48% had neither. Follicular carcinomas with PAX8-PPARγ typically showed immunoreactivity for galectin-3 but not for HBME-1, tended to present at a younger patient age and be smaller size, and were almost always overtly invasive. In contrast, follicular carcinomas with RAS mutations most often displayed an HBME-1-positive/galectin-3-negative immunophenotype and were either minimally or overtly invasive. Hürthle cell tumors infrequently had PAX8-PPARγ rearrangement or RAS mutations. These results suggest that conventional follicular thyroid carcinomas develop through at least two distinct and virtually nonoverlapping molecular pathways initiated by either RAS point mutation or PAX8-PPARγ rearrangement.

Original languageEnglish (US)
Pages (from-to)2318-2326
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume88
Issue number5
DOIs
StatePublished - May 1 2003

Fingerprint

Follicular Adenocarcinoma
Peroxisome Proliferator-Activated Receptors
Point Mutation
Tumors
Thyroid Gland
Galectin 3
Mutation
Neoplasms
Carcinoma
Codon
Adenoma
Genes
Immunohistochemistry
Technology

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors : Evidence for distinct molecular pathways in thyroid follicular carcinoma. / Nikiforova, Marina N.; Lynch, Roy A.; Biddinger, Paul W.; Alexander, Erik K.; Dorn, Gerald W.; Tallini, Giovanni; Kroll, Todd G.; Nikiforov, Yuri E.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 88, No. 5, 01.05.2003, p. 2318-2326.

Research output: Contribution to journalArticle

Nikiforova, Marina N. ; Lynch, Roy A. ; Biddinger, Paul W. ; Alexander, Erik K. ; Dorn, Gerald W. ; Tallini, Giovanni ; Kroll, Todd G. ; Nikiforov, Yuri E. / RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors : Evidence for distinct molecular pathways in thyroid follicular carcinoma. In: Journal of Clinical Endocrinology and Metabolism. 2003 ; Vol. 88, No. 5. pp. 2318-2326.
@article{e70bf8e0891b48e1af73d39893406cf0,
title = "RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma",
abstract = "A series of 88 conventional follicular and H{\"u}rthle cell thyroid tumors were analyzed for RAS mutations and PAX8-PPARγ rearrangements using molecular methods and for galectin-3 and HBME-1 expression by immunohistochemistry. A novel LightCycler technology-based method was developed to detect point mutations in codons 12/13 and 61 of the H-RAS, K-RAS, and N-RAS genes. Forty-nine percent of conventional follicular carcinomas had RAS mutations, 36{\%} had PAX8-PPARγ rearrangement, and only one (3{\%}) had both. In follicular adenomas, 48{\%} had RAS mutations, 4{\%} had PAX8-PPARγ rearrangement, and 48{\%} had neither. Follicular carcinomas with PAX8-PPARγ typically showed immunoreactivity for galectin-3 but not for HBME-1, tended to present at a younger patient age and be smaller size, and were almost always overtly invasive. In contrast, follicular carcinomas with RAS mutations most often displayed an HBME-1-positive/galectin-3-negative immunophenotype and were either minimally or overtly invasive. H{\"u}rthle cell tumors infrequently had PAX8-PPARγ rearrangement or RAS mutations. These results suggest that conventional follicular thyroid carcinomas develop through at least two distinct and virtually nonoverlapping molecular pathways initiated by either RAS point mutation or PAX8-PPARγ rearrangement.",
author = "Nikiforova, {Marina N.} and Lynch, {Roy A.} and Biddinger, {Paul W.} and Alexander, {Erik K.} and Dorn, {Gerald W.} and Giovanni Tallini and Kroll, {Todd G.} and Nikiforov, {Yuri E.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1210/jc.2002-021907",
language = "English (US)",
volume = "88",
pages = "2318--2326",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors

T2 - Evidence for distinct molecular pathways in thyroid follicular carcinoma

AU - Nikiforova, Marina N.

AU - Lynch, Roy A.

AU - Biddinger, Paul W.

AU - Alexander, Erik K.

AU - Dorn, Gerald W.

AU - Tallini, Giovanni

AU - Kroll, Todd G.

AU - Nikiforov, Yuri E.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - A series of 88 conventional follicular and Hürthle cell thyroid tumors were analyzed for RAS mutations and PAX8-PPARγ rearrangements using molecular methods and for galectin-3 and HBME-1 expression by immunohistochemistry. A novel LightCycler technology-based method was developed to detect point mutations in codons 12/13 and 61 of the H-RAS, K-RAS, and N-RAS genes. Forty-nine percent of conventional follicular carcinomas had RAS mutations, 36% had PAX8-PPARγ rearrangement, and only one (3%) had both. In follicular adenomas, 48% had RAS mutations, 4% had PAX8-PPARγ rearrangement, and 48% had neither. Follicular carcinomas with PAX8-PPARγ typically showed immunoreactivity for galectin-3 but not for HBME-1, tended to present at a younger patient age and be smaller size, and were almost always overtly invasive. In contrast, follicular carcinomas with RAS mutations most often displayed an HBME-1-positive/galectin-3-negative immunophenotype and were either minimally or overtly invasive. Hürthle cell tumors infrequently had PAX8-PPARγ rearrangement or RAS mutations. These results suggest that conventional follicular thyroid carcinomas develop through at least two distinct and virtually nonoverlapping molecular pathways initiated by either RAS point mutation or PAX8-PPARγ rearrangement.

AB - A series of 88 conventional follicular and Hürthle cell thyroid tumors were analyzed for RAS mutations and PAX8-PPARγ rearrangements using molecular methods and for galectin-3 and HBME-1 expression by immunohistochemistry. A novel LightCycler technology-based method was developed to detect point mutations in codons 12/13 and 61 of the H-RAS, K-RAS, and N-RAS genes. Forty-nine percent of conventional follicular carcinomas had RAS mutations, 36% had PAX8-PPARγ rearrangement, and only one (3%) had both. In follicular adenomas, 48% had RAS mutations, 4% had PAX8-PPARγ rearrangement, and 48% had neither. Follicular carcinomas with PAX8-PPARγ typically showed immunoreactivity for galectin-3 but not for HBME-1, tended to present at a younger patient age and be smaller size, and were almost always overtly invasive. In contrast, follicular carcinomas with RAS mutations most often displayed an HBME-1-positive/galectin-3-negative immunophenotype and were either minimally or overtly invasive. Hürthle cell tumors infrequently had PAX8-PPARγ rearrangement or RAS mutations. These results suggest that conventional follicular thyroid carcinomas develop through at least two distinct and virtually nonoverlapping molecular pathways initiated by either RAS point mutation or PAX8-PPARγ rearrangement.

UR - http://www.scopus.com/inward/record.url?scp=0012683188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0012683188&partnerID=8YFLogxK

U2 - 10.1210/jc.2002-021907

DO - 10.1210/jc.2002-021907

M3 - Article

C2 - 12727991

AN - SCOPUS:0012683188

VL - 88

SP - 2318

EP - 2326

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -